ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcturus Therapeutics Holdings Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.42+0.08 (+0.77%)
Close on Oct 19, 2026
- Market cap
- $296.17M
- P/E (TTM)
- –
- Dividend yield
- –
Arcturus Therapeutics Holdings Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue [Member] | $18.72M | $42.35M | $67.22M | $85.14M | $109.80M | $131.27M | $138.39M | $142.47M | $147.03M | $110.62M | $157.75M | $292.72M | 63.8% | -82.9% |
| Grant Revenue [Member] | $10.64M | $12.36M | $14.81M | $12.46M | $12.32M | $12.41M | $13.92M | $17.93M | $16.84M | $13.91M | $9.05M | – | 36.2% | -13.6% |
By region
From the segment and revenue-disaggregation notes of Arcturus Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.